Catalyst Pharmaceuticals (NYSE: CPRX) — Perfil da empresa, notícias e dados financeiros
Catalyst Pharmaceuticals develops therapies for rare genetic diseases, focusing on innovative treatments like Firdapse for LEMS.
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals (NASDAQ:CPRX) specializes in developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. With a primary focus on addressing unmet medical needs, their notable product, Firdapse, is a treatment designed to improve muscle strength in patients suffering from Lambert-Eaton myasthenic syndrome (LEMS). The company is committed to expanding its product portfolio through rigorous research and development initiatives, aiming to enhance the quality of life for patients dealing with severe diseases. Catalyst Pharmaceuticals is continually working on bringing new solutions to the market and supporting the communities they serve through patient-centric programs and advocacy.
Resumo
Operações
Produtos e/ou serviços de Catalyst Pharmaceuticals
- Firdapse for treating Lambert-Eaton myasthenic syndrome (LEMS) in adults, improving muscle function and reducing weakness.
- Ruzurgi, aimed for pediatric patients with Lambert-Eaton myasthenic syndrome (LEMS), focusing on patients ages 6 to less than 17.
- Generic version of Sabril (vigabatrin), focused on combating complex partial seizures and infantile spasms, offering an alternative treatment option.
- Development of CPP-109 (Vigabatrin) focused on treating addiction, showcasing a unique approach to addressing substance abuse disorders.
- Exploration in treatments for congenital myasthenic syndromes (CMS), aiming to expand their portfolio towards rare neuromuscular diseases.
- Investigative research on potential therapies for Myasthenia Gravis (MG), demonstrating commitment to addressing autoimmune neuromuscular disorders.
equipe executiva do Catalyst Pharmaceuticals
- Mr. Richard John Daly M.B.A.President, CEO & Director
- Mr. Michael W. Kalb CPAExecutive VP, Treasurer & CFO
- Dr. Steven R. Miller Ph.D.Executive VP, COO & Chief Scientific Officer
- Mr. Jeffrey Del CarmenExecutive VP & Chief Commercial Officer
- Dr. Preethi Sundaram Ph.D.Chief Strategy Officer
- Ms. Mary ColemanVP & Head of Investor Relations
- Mr. Brian Elsbernd J.D.Chief Compliance Officer & Chief Legal Officer
- Mr. Gregg RussoChief Human Resources Officer
- Dr. William T. Andrews FACP, M.D.Chief Medical Officer
- Mr. Philip B. Schwartz Esq.Corporate Secretary
Últimas notícias sobre a Catalyst Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Catalyst Pharmaceuticals, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 589 mi | 257,8 mi | 214,3 mi | |
| 491,7 mi | 195,1 mi | 163,9 mi | |
| 398,2 mi | 86,8 mi | 71,4 mi | |
| 214,2 mi | 101,8 mi | 83,1 mi |